Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01413516 · ClinicalTrials.gov registry record · Phase 2
Varenicline In-Patient Study
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01413516: Completed Phase 2 study, sponsored by Stanford University.
NCT01413516 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01413516, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).
Interventions
- DRUG Placebo
- DRUG Varenicline
- BEHAVIORAL Smoking cessation counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01413516
The ClinicalTrials.gov registry entry for NCT01413516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01413516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01413516 about?
NCT01413516 is a clinical study titled "Varenicline In-Patient Study". This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).
What is the current status of trial NCT01413516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2011-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01413516?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Smoking cessation counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT01413516?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.